Chengdu Kanghong Pharmaceutical Group Co., Ltd.
Clinical trials sponsored by Chengdu Kanghong Pharmaceutical Group Co., Ltd., explained in plain language.
A Chinese pharmaceutical company focused on drugs, including ophthalmology and oncology treatments.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug KHN707 enters first human safety trial in china Results expected Oct 2026 (estimated)
-
Can a 14-Day pill lift postpartum depression?
Disease control CompletedThis trial tests whether an experimental drug called KH607 can reduce symptoms of postpartum depression in adult women. Participants take the drug or a placebo once daily for two weeks. The study measures changes in depression scores to see if KH607 offers a safe and effective sh…
Phase 2 • Sponsor: Chengdu Kanghong Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Can an experimental pill lift the fog of severe depression? a new trial puts KH607 to the test.
Symptom relief CompletedThis phase 2 trial is evaluating whether an experimental drug called KH607 can safely reduce symptoms of depression in adults with moderate or severe major depressive disorder. The study has two parts: first, all participants receive KH607 openly to check safety and how the drug …
Phase 2 • Sponsor: Chengdu Kanghong Pharmaceutical Group Co., Ltd. • Aim: Symptom relief
Last updated Jul 30, 2026 00:00 UTC